BOULDER, CO / ACCESSWIRE / September 11, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, in partnership with EMC Pharma, LLC, today announced they have entered into a co-marketing agreement to launch and sell an expanded prescription and OTC eye care product line. The new eye care line will also feature refreshed design and improved packaging for Ocucyn® Eyelid & Eyelash Cleanser.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
Jeff Ameen Spire Wealth Management | 1,040 | $27,142.47 | $37,702.91 | $10,560.44 | 38.91% |
| RWL Richard W. Lowrie Park Edge Advisors LLC | 7,455 | $176,981.68 | $265,472.55 | $88,490.87 | 50% |
Menachem Striks Morton Capital Management LLC/CA | 16,314 | $407,515.34 | $580,941.54 | $173,426.2 | 42.56% |
Janice M. Powell Diversify Advisory Services, LLC | 11,177 | $293,246.6 | $398,012.97 | $104,766.37 | 35.73% |
| SPC Spirepoint Private Client LLC SPIREPOINT PRIVATE CLIENT, LLC | 6,676 | $206,204 | $237,732.36 | $31,528.36 | 15.29% |
| ARCA Exchange | US Country |
The fund is an exchange-traded fund (ETF) that operates with an active management approach, under the guidance of its Adviser and the expertise of its Sub-Adviser, focusing primarily on the goal of generating returns for its investors. This ETF is distinct in its commitment to investing significantly in the emerging markets sphere. It aims to allocate at least 80% of its net assets, alongside any borrowings purposed for investment, into equity securities that have a direct correlation with emerging market economies. These investments are carefully chosen based on their potential for growth and are diversified across issuers located in emerging markets or those entities that are fundamentally tied economically to these regions. The strategic approach is to capitalize on the dynamic nature of emerging markets to achieve its investment objective.
This product focuses on the direct investment in equity securities of companies that are based in, or operate predominantly within, emerging market countries. These markets are identified based on their rapid growth potential and increasing integration into the global economy. The fund's strategy involves identifying companies with solid fundamentals, strong growth prospects, and the ability to outperform within their respective markets.
This category encompasses investments in equity securities of companies that, while possibly headquartered or listed in developed markets, have substantial economic exposure to emerging markets. This includes companies with significant operations, revenue streams, or market interests in emerging economies. The aim is to capture the growth potential of emerging markets through companies that benefit from their economic dynamics but operate under the regulatory and governance standards of developed markets.